Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the ...
Umeclidinium-Vilanterol Inhaler May Reduce COPD Exacerbations Compared With Other LAMA-LABA Inhalers
Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...
Bespak is increasing pressurized metered dose inhaler manufacturing capacity to support Chiesi Group’s Carbon Minimal Inhaler (CMI) program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results